NCT06318533View on ClinicalTrials.gov

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

March 13, 2026

Study Completion Date

March 13, 2027

Conditions
Autoimmune Diseases
Interventions
DRUG

anti-CD19 CAR NK cells

Patients will receive Fludarabine (30mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3, followed by Anti-CD19 CAR NK cells infusion.

Trial Locations (2)

212001

RECRUITING

Affiliated Hospital of Jiangsu University, Zhenjiang

RECRUITING

Jiangsu University Affiliated Hospital, Zhenjiang

All Listed Sponsors
collaborator

Rui Therapeutics Co., Ltd

INDUSTRY

lead

YANRU WANG

OTHER